Aurinia Pharmaceuticals Inc (AUPH)

[Zeppo]

Those concerns are why AUPH didn't hold above $10 after the Phase II results were posted. It was in the 4s and now has rallied only back to the high 6s. No serious mention of its implications for eye disorders was even brought to the table. The Phase III test was created to succeed. Having done extensive reading on the subject since becoming a shareholder, I believe AUPH has a superior product. Should VOC be approved for all indications, I really don't know where the "greed" factor would kick in....supposedly.